http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1282581-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76195fd1cd08192222699d8e7a88c231 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C247-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-58 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-56 |
filingDate | 1969-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 1972-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | GB-1282581-A |
titleOfInvention | Adamantanopyrrolidenes |
abstract | 1282581 Condensed adamantane-pyrrolidines E R SQUIBB & SONS Inc 24 July 1969 [24 July 1968] 32940/69 Heading C2C Novel compounds I (including acid addition and quaternary ammonium salts thereof) wherein Y is C 3-10 cycloalkyl, allyl, R 0 and R are H, alkyl, alkoxy or phenyl, m is 0 or 1 to 4, n is 1 to 4, B signifies -NR 1 R 2 or 5-, 6- or 7-membered N-heterocyclic radical (may be substituted and has less than 12 atoms excluding H atoms) and R 1 and R 2 are H, alkyl or adamantyl, are obtained: (a) by ring closing compounds II (prepared, e.g. by reacting the corresponding secondary amine with N-chlorosuccinimide; R 3 is alkyl, e.g. ethyl) in the presence of 85% sulphuric acid or by utilizing photolysis to afford I in which Y is alkyl; dealkylation affords I in which Y is H; (b) by ring closing azides III (obtained by reacting the appropriate 1-adamantane-ethanol tosylate with sodium or potassium azide) to afford I in which Y is H; (c) by reducing a pyrrolidone IV with lithium aluminium hydride which pyrrolidone is itself obtained by irradiation of acid azide V (obtained from the corresponding acid chloride) with ultra-violet light or (d) by reacting I in which Y is H with halogen-Y (Y is not H). The foregoing secondary amine (the hydrochloride thereof is also described) is obtained by treating N - [2 - (1 - adamantane)ethyl] - acetamide (prepared via the following compounds: 1- adamantane-acetic acid, acid chloride thereof, 1- adamantane-acetamide and 1-adamantane-ethylamine; the latter, the hydrochloride of which is also described, is then treated with acetyl chloride) with lithium aluminium hydride. The foregoing tosylate is obtained by the interaction of p-toluenesulphonyl chloride and 1- adamantane-ethanol (prepared by interacting 1- adamantane-acetic acid and lithium aluminium hydride). Pharmaceutical preparations useful as antiviral agents contain as active ingredient compounds I; administration is, e.g. orally or parenterally or by vapour or spray through the mouth or nasal passages. |
priorityDate | 1968-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.